The study, published in Clinical Research in Cardiology, followed 113 patients treated with an Impella microaxial flow pump between January 2021 and December 2023. All patients had cardiogenic shock classified as stage C or higher on the Society for Cardiovascular Angiography and Interventions scale, meaning their circulatory failure was severe enough to require mechanical assistance. The researchers measured four cytokines, interleukin-1β, interleukin-6, interleukin-8, and tumor necrosis factor-α, at five predefined time points: at device implantation and then at 24, 72, 120, and 168 hours afterwards. Serum samples were analyzed using chemiluminescent immunoassays on a Siemens IMMULITE 2000 XPi system, allowing precise quantification of even low cytokine concentrations.

The biological rationale for the study rests on a growing recognition that cardiogenic shock is more than a plumbing failure. Myocardial ischemia and reperfusion release damage-associated molecular patterns that activate innate immune pathways, triggering a flood of proinflammatory mediators. These cytokines, including interleukin-6 and tumor necrosis factor-α, are associated with myocardial depression, vasoplegia, endothelial dysfunction, and microcirculatory impairment, all of which are closely linked to organ failure and death. The problem is that current shock classification frameworks, such as the SCAI staging system and guideline-based strategies from the American and European cardiology societies, rely almost exclusively on hemodynamic and metabolic parameters. They capture how badly the circulation is failing but say little about the underlying inflammatory injury that may be driving the patient toward irreversible decline.

The results revealed a clear temporal pattern. At the moment of implantation, tumor necrosis factor-α was the only cytokine significantly elevated in patients who would later die. By 24 hours, both interleukin-6 and tumor necrosis factor-α were higher in non-survivors. The divergence peaked at 72 hours, driven overwhelmingly by interleukin-6, which showed the most pronounced, sustained, and temporally consistent separation of any molecule measured. At 120 hours, interleukin-6 remained the only cytokine still discriminating between outcomes, and by 168 hours no cytokine showed significant differences. Interleukin-1β never differed between groups at any time point, likely because it is released locally and transiently, whereas interleukin-6 acts as a downstream amplifier that better reflects sustained systemic inflammation.

The statistical analysis strengthened the clinical significance of this signal. Using time-point-specific multivariable logistic regression models designed to avoid collinearity between repeated measurements, the researchers found that log-transformed interleukin-6 was already an independent predictor of 30-day mortality at 24 hours, with an odds ratio of 3.07. At 72 hours, the model was most robust: interleukin-6 carried an odds ratio of 4.68 and lactate an odds ratio of 2.74, while C-reactive protein and procalcitonin lost their significance. Receiver operating characteristic analysis at 72 hours yielded an area under the curve of 0.745 and identified an optimal cut-off of 164.5 picograms per milliliter, with 68.0 percent sensitivity and 82.1 percent specificity. In exploratory landmark-type Kaplan–Meier analysis, patients above this threshold had markedly lower 30-day survival, with a log-rank p value below 0.001.

Perhaps most importantly, interleukin-6 added prognostic value beyond the markers clinicians already use. The researchers compared a base model containing age, lactate, and the vasoactive-inotropic score, a composite measure of pharmacological hemodynamic support, against an extended model that also included interleukin-6. Adding the cytokine improved the area under the curve from 0.79 to 0.82 and significantly improved overall model fit according to the likelihood-ratio test. Notably, the vasoactive-inotropic score was no longer statistically significant in the fully adjusted model, suggesting that the inflammatory signal captured information about patient trajectory that the intensity of drug support alone could not. Interaction analyses showed that the association between interleukin-6 and mortality was not modified by hemodynamic severity or by blood culture positivity.

That last finding addresses one of the thorniest questions in shock medicine: is the inflammation driven by the shock itself, or by a hidden infection? Blood cultures were obtained in 90 of the 113 patients, and 16 of those cultures were positive, predominantly with gram-positive organisms such as Staphylococcus epidermidis and Cutibacterium acnes. There was no difference in culture positivity between survivors and non-survivors, and interleukin-6 concentrations showed no consistent association with blood culture status. The authors are careful, however, not to overinterpret this. Blood cultures are an imperfect marker of infection, and the retrospective design meant that culture-negative infections, contamination, ventilator-associated infections, and the effects of antibiotic exposure could not be systematically excluded. Persistent interleukin-6 elevation, they conclude, should be read as a marker of ongoing inflammatory activation that may reflect sterile shock inflammation, unrecognized infection, or vasoplegic physiology.

The study also offers a window into how the devices themselves might interact with the immune system. Non-survivors required higher pump performance levels at the first follow-up assessments, likely reflecting higher rotational speeds, and non-physiological shear stress and hemolysis are known to modulate inflammatory signaling. Yet because every patient in the cohort received a microaxial pump and there was no control group, the study cannot determine whether the support itself attenuates, amplifies, or merely accompanies the inflammatory response. The cohort also had a comparatively low 30-day mortality rate of 26.5 percent, which the authors attribute to selection: patients on veno-arterial ECMO, those supported for less than 24 hours, and the most refractory stage E patients were all excluded. Non-survivors in the study were older, had lower ejection fractions, higher SOFA scores, and more often required continuous hemodiafiltration, consistent with greater baseline vulnerability.

The findings arrive at a moment when the field is recalibrating its expectations for mechanical circulatory support. The randomized DanGer Shock trial demonstrated that microaxial pump support can improve outcomes in selected patients with infarct-related shock, but benefit depends on timing, etiology, and overall severity, while the CHIP-BCIS3 trial of elective unloading during complex percutaneous coronary intervention did not reduce major adverse events. Against that backdrop, the Marburg results suggest that biology, not just hemodynamics, may determine who benefits. The authors emphasize that interleukin-6 at 72 hours should not be used as the sole criterion for starting, withholding, or modifying support. Instead, a persistently elevated value should trigger structured clinical reassessment, including evaluation of support adequacy, catecholamine exposure, residual ischemia, infection, and device complications.

The study’s limitations are acknowledged candidly. It was single-center and retrospective, exact intervals from symptom onset to implantation were unavailable, and attrition reduced statistical power at later time points. Only preselected cytokines were measured, leaving out potentially relevant mediators such as interleukin-10, and serial cardiac biomarkers were not standardized across all time points. The 164.5 picogram per milliliter threshold requires external validation and assay standardization before it can enter routine practice. Still, the central message is compelling: in patients whose hearts are being mechanically supported, the immune system’s trajectory over the first three days tells a story that blood pressure and lactate alone cannot. Serial interleukin-6 measurement, the authors conclude, is a hypothesis-generating tool that may finally give clinicians a biological window into which shock patients are recovering and which are quietly sliding toward a fate that no pump, however sophisticated, can reverse on its own.

Subject of Research: Cytokine trajectories and inflammatory risk stratification in cardiogenic shock patients supported by microaxial flow pumps

Article Title: Temporal cytokine trajectories during microaxial flow pump support identify a high-risk inflammatory phenotype in cardiogenic shock

Article References: Kreutz, J., Amoah, J., Mihali, K., Harbaum, L., Chatzis, G., Patsalis, N., Syntila, S., Schieffer, B., & Markus, B. (2026). Temporal cytokine trajectories during microaxial flow pump support identify a high-risk inflammatory phenotype in cardiogenic shock. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03040-z

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03040-z

Keywords: cardiogenic shock, interleukin-6, microaxial flow pump, mechanical circulatory support, cytokines, inflammation, prognostic markers, 30-day mortality, Impella, biomarkers, SCAI classification, lactate

The study, led by Jun Liu, Wenheng Chen and Shan Gao of Zhumadian Central Hospital in China, followed 624 patients who underwent primary unilateral total knee arthroplasty, the technical term for a complete artificial knee replacement. Instead of relying only on pain intensity scores, the researchers asked patients to complete whole-body pain drawings at two weeks, six weeks, and three months after their operation. On these standardized body silhouettes, patients shaded every region where they had felt pain during the previous week. A semiautomated image-processing pipeline built on Python, OpenCV, SimpleITK and scikit-image then scanned, aligned and quantified these drawings, converting the shaded areas into a single number called the Pain Extent Index, or PEI: the percentage of body surface area marked as painful.

The technical machinery behind this measurement was rigorous. Paper drawings were scanned at high resolution and electronic drawings were exported as lossless image files, then corrected for orientation, stripped of stray annotations, and registered to a standardized anatomical template using affine and nonrigid registration. Every processed map passed through structured quality control, with flagged images independently reviewed and resolved by consensus. Reproducibility testing on a 20 percent sample of patients produced strikingly high agreement: the inter-rater intraclass correlation coefficient for the PEI was 0.987, and the median Dice coefficient, a measure of overlap between independently processed pain masks, was 0.949. In other words, two different analysts processing the same drawing arrived at nearly identical maps of where the patient hurt.

With the PEI quantified at each visit, the team calculated a patient-specific contraction velocity, essentially the rate at which the spatial footprint of pain shrank between two weeks and three months. This was done with linear mixed-effects modeling, a statistical technique that estimates both a population-average trajectory and an individual slope for each patient. Across the whole cohort, the median contraction rate was about 0.065 log units per week, meaning most patients’ pain maps contracted substantially during the subacute phase. But the spread was wide, and that spread turned out to matter enormously. Patients who went on to report moderate-to-severe knee pain at twelve months contracted at only about half the rate of those who recovered well, and roughly one in five of them actually showed spatial pain expansion rather than contraction.

The headline result is statistically robust. At twelve months, 92 patients, or 14.7 percent of the cohort, met the strict definition of persistent moderate-to-severe operated-knee pain, which required a pain score of at least four out of ten, pain on at least four days per week, and continuous or recurrent pain lasting at least three months. Each standard deviation of slower spatial contraction was associated with 42 percent higher odds of falling into this group, even after the researchers adjusted for age, sex, body mass index, comorbidities, preoperative pain intensity, preoperative pain extent, psychological factors such as catastrophizing and anxiety, neuropathic pain features, and crucially, the static pain measurements taken at both ends of the recovery window. That final adjustment is the study’s key innovation: knowing where a patient’s pain stood at two weeks and at three months still did not explain away the signal carried by the rate of change itself.

The pattern held up under an unusually thorough battery of sensitivity analyses. The association persisted when the exposure was redefined as absolute PEI change, relative contraction rate, time-weighted pain-area burden, or slopes restricted to the operated limb or the knee alone. A Bayesian joint model that explicitly accounted for uncertainty in the estimated slopes yielded a similar result, with a posterior odds ratio of 2.05. When the researchers excluded the twelve patients whose twelve-month pain had an adjudicated alternative explanation, such as infection or a mechanical prosthesis problem, the association actually strengthened. Inverse-probability weighting to address missing data, and separate analyses of paper versus electronic drawings, all produced consistent estimates, suggesting the finding is not an artifact of one analytical choice.

Just as striking were the secondary outcomes. Slower spatial contraction predicted higher knee pain scores at both six and twelve months, lower scores on the KOOS-JR joint-replacement quality-of-life questionnaire, and lower Forgotten Joint Scores, which measure how completely patients stop noticing their artificial joint in daily life. Each standard deviation of slower contraction was associated with a 4.6-point drop in KOOS-JR and a 6.3-point drop in the Forgotten Joint Score, and it raised the odds of failing to achieve a clinically meaningful improvement in joint function by 46 percent. The population-level heat maps tell the story visually: in patients who recovered well, pain density around the knee swelled briefly after surgery and then collapsed toward a low plateau, while in those with persistent pain the map remained stubbornly wide from three months onward.

Why should the spatial spread of pain carry prognostic power that intensity scores lack? The authors are careful not to overclaim a mechanism, but they outline several plausible biological pathways. A pain map that refuses to shrink could reflect persistent peripheral input from the healing joint, such as ongoing inflammation or synovitis. It could indicate guarding and altered movement patterns that spread mechanical load to the thigh, lower leg and contralateral side. It could also signal central sensitization, a state in which the nervous system itself amplifies and generalizes pain signals, a phenomenon long implicated in poor arthroplasty outcomes and connected to psychological distress. A whole-body slope cannot distinguish these mechanisms, but it may integrate them into a single, clinically readable signal of whether recovery is genuinely progressing.

The clinical implications are tantalizing but deliberately cautious. Serial pain drawings are cheap, quick and, as this study demonstrates, remarkably reproducible whether collected on paper or digitally, making them a plausible addition to routine follow-up visits or even remote monitoring programs. A patient whose pain map is contracting slowly at the six-week check could prompt clinicians to look harder for wound complications, prosthesis problems, stiffness, neuropathic features, sleep disturbance or rehabilitation barriers, rather than simply waiting for the twelve-month appointment to reveal a bad outcome. The authors stress that a slow contraction rate is a signal to investigate, not a diagnosis, and certainly not an indication for automatic imaging or revision surgery, since revision outcomes vary widely depending on the underlying cause of pain.

Important limitations temper the excitement. This was a single-center retrospective analysis of prospectively collected data, so residual confounding cannot be excluded, and the cohort may not generalize to other populations or healthcare systems. Summarizing recovery with a linear slope from three time points inevitably smooths over nonlinear dynamics, and pain drawings ultimately depend on patient comprehension and recall. The study also cannot establish causality: slow contraction may be a cause of chronic pain, a consequence of an underlying pathological process, or simply another face of the same phenomenon. What it does establish is that the direction and speed of spatial pain recovery carry real prognostic information beyond anything measured at a single visit. If future multicenter studies validate the approach and demonstrate that acting on an early contraction alert improves outcomes, the humble body diagram, a tool as old as clinical medicine itself, could become a powerful digital window into how recovery is truly unfolding.

Subject of Research: Association between early postoperative contraction of spatial pain extent and persistent moderate-to-severe knee pain 12 months after total knee arthroplasty

Article Title: Early spatial pain contraction and moderate-to-severe knee pain 12 months after total knee arthroplasty: a retrospective cohort study

Article References: Liu, J., Chen, W., & Gao, S. (2026). Early spatial pain contraction and moderate-to-severe knee pain 12 months after total knee arthroplasty: a retrospective cohort study. Frontiers in Pain Research, 7, Article 1948322. https://doi.org/10.3389/fpain.2026.1948322

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1948322

Keywords: total knee arthroplasty, chronic postsurgical pain, pain extent index, pain drawings, spatial pain contraction, subacute recovery, central sensitization, KOOS-JR, prognostic markers, knee osteoarthritis, pain trajectories, mixed-effects modeling

The study reviewed patients diagnosed with tissue-confirmed central neurocytoma between 1990 and 2025 across the two institutions. Fifty-one patients made up the final cohort, with a median age at diagnosis of just 26 years and a remarkable median follow-up of 9.7 years, a duration that few single-institution series of this rare tumor have achieved. That long observational window matters enormously for a tumor that can recur years, even decades, after initial treatment. The researchers calculated recurrence-free survival and overall survival using Kaplan-Meier methods, the standard statistical approach for tracking how many patients remain free of disease over time, and then applied multivariate Cox regression analysis to a pre-planned set of variables to determine which factors independently influenced the risk of the tumor coming back.

The headline survival numbers remain genuinely encouraging. Overall survival for the entire cohort stood at 94 percent at ten years, meaning that despite the tumor’s location in a surgically treacherous part of the brain and its tendency to recur, death from this disease is uncommon. Central neurocytomas sit within or adjacent to the lateral ventricles, the cavities that produce and circulate cerebrospinal fluid, and surgery there carries risks of hydrocephalus, bleeding, and injury to deep brain structures. Yet the long-term mortality data confirm that for most patients, this is a disease to be managed rather than feared, provided that recurrences are caught and treated promptly.

Recurrence, however, proved to be a much more common companion than the field has generally acknowledged. Among patients who did not receive adjuvant radiotherapy after surgery, the five-year recurrence-free survival was 61 percent following gross total resection, the operation in which the surgeon removes all visibly identifiable tumor, versus 46 percent after subtotal resection, where some tumor is deliberately or unavoidably left behind. The difference between the two surgical outcomes did not reach statistical significance in this cohort, with a P value of 0.18, but the absolute numbers are striking. A 39 percent chance of recurrence within five years after a supposedly complete removal contradicts the widely held assumption that gross total resection alone is curative, and it directly challenges previous reports that have portrayed recurrence after complete surgery as an exception rather than a rule.

The multivariate analysis sharpened the picture by isolating four independent predictors of worse recurrence-free survival. Omission of adjuvant radiotherapy carried a hazard ratio of 9.0, meaning patients who did not receive postoperative radiation were nine times more likely to experience recurrence, with a P value of 0.003. Subtotal resection carried a hazard ratio of 5.7, statistically significant at P equals 0.017. Younger age at diagnosis was associated with a hazard ratio of 3.1, significant at P equals 0.002, an intriguing finding suggesting that the biology of these tumors in younger patients may be more aggressive than their histological appearance implies. Finally, a higher Ki-67 proliferation index, a pathologist’s measure of how many tumor cells are actively dividing, carried a hazard ratio of 1.13 per unit increase, significant at P equals 0.017, confirming that the biological activity of the tumor itself, not merely the extent of surgery, shapes the risk of relapse.

The Ki-67 finding deserves particular attention because it connects this study to a long-running debate in neuropathology. Ki-67 is a protein expressed by cells in the active phases of the cell cycle, and the labeling index, the percentage of tumor nuclei that stain positive for it, has been used for decades to distinguish indolent from more aggressive gliomas. For central neurocytomas, earlier work had suggested that tumors with elevated MIB-1 labeling, the antibody used to detect Ki-67, behave more aggressively and deserve the designation of atypical neurocytoma. The new multi-institutional data lend substantial statistical weight to that idea, showing that even within a WHO grade 2 classification, the proliferative index carries real prognostic information that should inform how closely a patient is monitored and whether additional therapy is considered up front.

Perhaps the most clinically actionable result concerns what happens after the first recurrence. Among the 17 patients in the cohort who received salvage radiotherapy, radiation delivered at the time of their first relapse rather than immediately after initial surgery, the five-year recurrence-free survival after that salvage treatment was 83 percent, with a median follow-up of 4.8 years. In other words, holding radiation in reserve until the tumor actually returns produced durable long-term control for the large majority of patients. This strategy, sometimes called deferred or salvage treatment, spares patients the potential toxicities of brain radiotherapy, which can include cognitive effects and injury to surrounding healthy tissue, during the years when they are most likely to be building careers and families. For a tumor diagnosed at a median age of 26, deferring radiation without compromising ultimate control is a meaningful quality-of-life win.

The findings arrive amid a broader re-evaluation of how central neurocytomas should be managed. Recent multicenter studies from Korea and France have reported improved tumor control with adjuvant radiotherapy, and an earlier 35-year experience from the Mayo Clinic itself had generated management recommendations favoring consideration of postoperative radiation in selected cases. The new study builds on that foundation with longer follow-up and a formal multivariate framework, and its results suggest a middle path: patients with favorable features, such as a gross total resection, a low Ki-67 index, and older age at diagnosis, may be safely observed with close surveillance imaging, while those with subtotal resections, high proliferative indices, or young age warrant a serious discussion about adjuvant radiotherapy given the ninefold increase in recurrence risk when it is omitted.

There are important caveats to keep in view. Fifty-one patients, though large for this ultra-rare tumor, is still a modest number, and the comparison between adjuvant radiotherapy and observation was not randomized; treatment decisions were made by clinicians and patients over three and a half decades, raising the possibility of selection bias in who received radiation. The hazard ratios, while statistically significant, come from retrospective data, and the authors themselves note that no new datasets were generated or analyzed beyond the clinical records reviewed. The difference in five-year recurrence-free survival between gross total and subtotal resection without radiotherapy did not reach significance, a reminder that even apparent clinical differences in rare-disease cohorts require cautious interpretation. Still, the consistency of the Ki-67 and age findings with prior literature strengthens the case that they reflect genuine biology rather than statistical noise.

For the young patients who make up the vast majority of those diagnosed with central neurocytoma, the practical message of this study is one of informed vigilance rather than alarm. Survival is excellent, ten-year mortality is low, and even tumors that return can usually be brought back under control with salvage radiotherapy. But the era of assuming that a clean surgical margin equals a cure appears to be over. The study’s authors, led by Yufan Yang of the University of Michigan and Northwestern University’s radiation oncology team together with colleagues at the Mayo Clinic, argue that their cohort represents one of the most comprehensive long-term pictures of this disease available anywhere. As molecular profiling increasingly refines the classification of even rare brain tumors, the proliferative index and the patient’s age at diagnosis are emerging as the numbers that matter most, and clinicians managing these tumors now have firmer statistical ground on which to decide who needs radiation now and who can safely wait.

Subject of Research: Long-term recurrence outcomes and prognostic predictors in central neurocytoma

Article Title: Long term outcomes and predictors of recurrence in central neurocytomas: a 35-year multi-institutional experience

Article References: Yang, Y., Leenstra, J. L., Brown, P. D., Wadhwani, N., Ho, A., & Sachdev, S. (2026). Long term outcomes and predictors of recurrence in central neurocytomas: a 35-year multi-institutional experience. Journal of Neuro-Oncology, 180(1), Article 19. https://doi.org/10.1007/s11060-026-05825-8

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05825-8

Keywords: central neurocytoma, brain tumor, recurrence, Ki-67, adjuvant radiotherapy, salvage radiotherapy, gross total resection, prognostic markers, neuro-oncology, WHO grade 2, Kaplan-Meier, Cox regression

The research team, led by radiation oncologist Rahmi Atıl Aksoy together with colleagues from radiation oncology and medical microbiology, followed 152 adults with glioblastoma who had completed a course of radiotherapy at their institution. Rather than relying on billing codes or broad clinical impressions, the investigators anchored their analysis to microbiological evidence: every infection counted in the descriptive part of the study was culture-positive, meaning that a pathogen had actually been isolated and identified in the laboratory. Patients were categorized over the twelve months following radiotherapy completion into three groups: those with a documented culture-positive infection, those who underwent a culture evaluation that came back negative, and those from whom no culture was ever obtained during the observation window.

The descriptive findings are the study’s most robust contribution and paint a strikingly consistent picture. Of the 152 patients, 48, or 31.6 percent, experienced at least one culture-positive infection within a year of finishing radiotherapy. Another 22 patients, 14.5 percent, had samples sent for culture that yielded no pathogen, while the majority, 82 patients or 53.9 percent, never had a culture obtained at all. Among the infections that were microbiologically confirmed, respiratory tract infections were the most common, accounting for 16 cases, closely followed by urinary tract infections with 15. This distribution is telling: rather than the brain abscesses or wound infections that might intuitively be associated with neurosurgery and irradiation of the head, the dominant infectious burden in this population arose in the lungs and the urinary tract, sites classically linked to hospitalization, catheterization, aspiration and declining performance status.

The microbiological profile reinforced that impression of a healthcare-associated flora. Of the 60 isolates recovered across the cohort, 41 were Gram-negative bacteria, a family of organisms that includes Escherichia coli, Klebsiella species and Pseudomonas aeruginosa and that is strongly associated with hospital environments, indwelling devices and broad-spectrum antibiotic pressure. Gram-negative organisms are also notorious for their resistance mechanisms, and the study’s focus on antimicrobial resistance patterns reflects a practical concern for clinicians: when a glioblastoma patient deteriorates with fever, the empirical antibiotics chosen at the bedside must cover organisms that are often far hardier than those circulating in the community. The predominance of respiratory and urinary sources, together with the Gram-negative skew, suggests that these infections are less a direct consequence of the tumor or its treatment of the brain itself and more a marker of the general frailty and healthcare exposure that accumulate as the disease progresses.

Beyond describing which microbes were present, the investigators asked a more provocative question: does a documented infection carry prognostic information? To address this, they moved beyond simple comparisons of groups defined at baseline, which are notoriously vulnerable to bias, and instead modeled infection status as a time-dependent covariate in a Cox proportional hazards framework. In practical terms, each patient’s status could change over the follow-up period: a person might begin in the no-culture-yet state, transition to a culture-positive or culture-negative state on the date a sample was collected, and contribute survival time in each state accordingly. This time-updated design prevents the classic immortal-time bias that arises when patients are classified by events that occur after the start of follow-up, and it allows the hazard of death to be estimated in relation to the current microbiological state rather than a fixed label assigned at the outset.

The results of that secondary analysis were dramatic. In the multivariable time-dependent model, adjusted for baseline variables that were significantly associated with overall survival in univariable screening, being in the culture-positive state was associated with a substantially higher hazard of subsequent death compared with the no-culture-yet state: an adjusted hazard ratio of 6.60, with a 95 percent confidence interval of 4.38 to 9.93 and a p value below 0.001. In other words, once a patient had a documented culture-positive infection, the rate of dying in the following period was more than six times higher than before such an infection was documented, after accounting for other measured prognostic factors. By contrast, a culture-negative evaluation, which indicates that a clinician suspected infection strongly enough to order cultures but no pathogen was recovered, was not significantly associated with mortality, with an adjusted hazard ratio of 1.65 and a confidence interval spanning 0.96 to 2.83.

The contrast between the two states is perhaps the most intellectually interesting aspect of the analysis. If the mere act of becoming sick enough to be sampled were driving the mortality signal, one might expect the culture-negative group to show a similar elevation, since those patients also presented with clinical concern sufficient to prompt microbiological workup. Instead, mortality in the culture-positive state was 4.01 times higher than in the culture-negative state, with a confidence interval of 2.22 to 7.22. This graded pattern, in which confirmed infection carries a far stronger association than suspected-but-unconfirmed infection, is consistent with the idea that the isolation of a true pathogen identifies a qualitatively more severe physiological insult, although the authors are careful not to overinterpret this hierarchy.

Recognizing that some deaths may have occurred within days of culture collection, potentially reflecting patients who were already moribund when sampled, the team performed a sensitivity analysis in which all state transitions were delayed by 30 days. This lagged design asks whether the association survives when deaths immediately following the sampling event are effectively excluded from the culture-positive exposure window. It did: the adjusted hazard ratio for the culture-positive state attenuated from 6.60 to 3.36, with a confidence interval of 2.09 to 5.39, but remained highly significant. The persistence of the signal after lagging argues against the crudest form of reverse causation, in which the infection is merely a terminal event rather than a contributor to decline, though it cannot eliminate subtler forms of the same problem.

The authors themselves are admirably explicit about the limits of their prognostic finding. Because cultures were obtained on clinical indication rather than on a fixed schedule, the sampling process itself is entangled with patient condition: sicker patients are more likely to be tested, and the decision to test is made by clinicians responding to deterioration. Residual confounding by performance status, steroid use, disease progression and other unmeasured factors remains possible, and reverse causation, in which advancing tumor drives both infection susceptibility and death, cannot be excluded in a retrospective design. For these reasons, the study’s conclusion frames the survival association as hypothesis-generating rather than causal. A documented culture-positive infection after radiotherapy should be understood as a marker of increased subsequent mortality, not as a proven independent killer.

Even with those caveats, the study has clear practical implications. For radiation oncologists and neuro-oncologists, the finding suggests that a confirmed infection in the months after chemoradiation is a meaningful clinical event that should prompt renewed attention to supportive care, medication review and candid conversations about goals of treatment, rather than being dismissed as an incidental complication. For microbiologists, the predominance of Gram-negative, respiratory and urinary, frequently healthcare-associated organisms provides an evidence base for empirical antibiotic choices in this population. And for researchers, the work establishes a methodological template: time-dependent modeling with lagged sensitivity analyses offers a rigorous way to interrogate the prognostic weight of complications that occur on a rolling timeline. Whether infection is purely a mirror of tumor progression or an active participant in it remains an open question, but this study ensures that the question will now be asked with far better data behind it.

Subject of Research: Microbiological profile of post-radiotherapy infections and their prognostic significance in glioblastoma

Article Title: Microbiological profile and prognostic significance of infections following radiotherapy in glioblastoma

Article References: Aksoy, R. A., Şahiner, M. B., Kahya, U. K., Koca, Ö., Koca, T., & Korcum, A. F. (2026). Microbiological profile and prognostic significance of infections following radiotherapy in glioblastoma. BMC Cancer. https://doi.org/10.1186/s12885-026-17033-8

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17033-8

Keywords: glioblastoma, radiotherapy, infection, microbiology, Gram-negative bacteria, antimicrobial resistance, overall survival, time-dependent Cox regression, prognostic markers, respiratory infections, urinary tract infections, healthcare-associated infections

The research team, led by Tomoko Nagamine and colleagues in the Department of Endocrinology, Metabolism and Nephrology, examined the records of 22 individuals diagnosed with thyroid storm between 2012 and 2024. That number may seem small, but it reflects the reality of a disease that strikes only a tiny fraction of patients with thyrotoxicosis, and it makes the study one of the more detailed single-center analyses of admission-time risk prediction in this population. The researchers classified outcomes into two groups: eighteen patients with favorable outcomes and four patients with poor outcomes, defined as in-hospital death or cardiopulmonary arrest requiring resuscitation, regardless of whether spontaneous circulation was subsequently restored.

To assess severity on arrival, the team applied four scoring systems that occupy different corners of acute medicine. The Acute Physiology and Chronic Health Evaluation II, or APACHE II, is a heavyweight intensive care score that combines twelve physiological measurements with age and chronic health status. The Sequential Organ Failure Assessment, or SOFA, tracks dysfunction across six organ systems with repeated measurements over time, while its abbreviated cousin, quick SOFA, distills the concept to three bedside variables: altered mentation, low systolic blood pressure, and rapid respiratory rate. The Burch–Wartofsky Point Scale, by contrast, was designed specifically for thyroid storm in the early 1990s and assigns points for features such as fever, tachycardia, atrial fibrillation, heart failure, delirium, and precipitating events.

The central finding was strikingly consistent: all four scores were significantly higher in the poor outcome group than in the favorable outcome group. In other words, every instrument captured some signal of impending catastrophe, whether it was built for general critical illness or tailored to thyroid derangement. This convergence matters because it suggests that the physiological chaos of thyroid storm leaves fingerprints across multiple domains of assessment, from respiratory and cardiovascular function to consciousness and renal performance, and that no single organ system tells the whole story.

When the researchers turned to exploratory receiver operating characteristic analysis, the standard statistical technique for judging how well a test discriminates between two groups, the Burch–Wartofsky Point Scale emerged with the highest discriminatory performance. A cutoff of 105 points or more identified poor outcomes with a reported sensitivity of 100 percent and a specificity of 94.4 percent, meaning that in this cohort every patient who went on to a catastrophic outcome scored above the threshold, while nearly all patients who recovered scored below it. The authors are careful to note that these estimates are constrained by the small number of poor outcomes, only four events, which inflates statistical uncertainty and demands validation in larger, independent cohorts before the threshold is adopted clinically.

Beyond the headline scores, the study mapped which clinical parameters traveled with adverse outcomes. Poor outcomes clustered with markers of spreading organ dysfunction: coagulopathy detected through abnormal prothrombin time, renal impairment, metabolic acidosis, impaired consciousness measured on the Glasgow Coma Scale, thrombocytopenia reflecting falling platelet counts, and atrial fibrillation, the chaotic upper-chamber rhythm that is both a classic feature of thyrotoxic cardiomyopathy and a harbinger of hemodynamic collapse. Each of these findings paints a picture of thyroid storm as a systemic disease in which excess circulating thyroid hormone drives a hypermetabolic state that then cascades into liver, kidney, blood, and brain injury.

The mechanistic story behind these associations is well understood in outline. Surging levels of triiodothyronine and thyroxine sensitize the heart to catecholamines, pushing cardiac output beyond sustainable limits while simultaneously impairing the heart’s ability to relax and fill. Fever and sweating cause fluid losses that compound hypotension. The resulting tissue hypoperfusion generates lactic acid, which appears as metabolic acidosis on arterial blood gas analysis. Meanwhile, the prothrombotic and proinflammatory milieu can tip coagulation pathways into dysfunction, and reduced hepatic clearance of clotting factors compounds the problem. Thrombocytopenia may signal both consumption and bone marrow suppression in the sickest patients. The study’s finding that these laboratory derangements distinguished survivors from nonsurvivors fits neatly into this physiological framework.

For emergency physicians and intensivists, the practical implication is that the Burch–Wartofsky Point Scale, despite being three decades old and never originally validated against hard outcomes, may carry prognostic information beyond its diagnostic role. The scale was conceived as a case-finding instrument, a way to decide whether a febrile, tachycardic patient with Graves’ disease has crossed into storm territory. The new data suggest that a markedly elevated score, well above the traditional diagnostic threshold, does not merely confirm the diagnosis but also flags a patient whose physiology is already failing in ways that predict death or arrest. In a disease where mortality historically approached 20 to 30 percent and hinges on rapid administration of thionamides, beta-blockers, iodine, and corticosteroids, any tool that accelerates triage toward intensive care could be consequential.

The study also carries methodological lessons for the field. Thyroid storm is so rare that no single center can assemble the hundreds of patients needed for definitive prognostic modeling, which is why the authors explicitly frame their receiver operating characteristic estimates as exploratory and call for validation in larger independent cohorts. Multicenter registries, such as those maintained by the Japan Endocrine Society and the Japanese Thyroid Association, whose diagnostic criteria informed the case definitions in this work, represent the most plausible path forward. Combining the disease-specific sensitivity of the Burch–Wartofsky scale with the organ-failure granularity of SOFA might ultimately yield a hybrid score that outperforms either instrument alone, a hypothesis the present data cannot test but clearly motivate.

Until such validation arrives, the message for clinicians is one of layered vigilance. Every patient with thyroid storm requires immediate intensive management, as the authors emphasize, but the admission Burch–Wartofsky Point Scale may provide additional information for early risk stratification, particularly when scores climb toward or beyond the 105-point threshold identified here. Coupled with close attention to coagulation parameters, renal function, acid–base status, mental status, platelet counts, and cardiac rhythm, the scale could help clinicians decide which patients need escalation to continuous hemodiafiltration, plasma exchange, or mechanical circulatory support before collapse occurs. In a condition where hours separate recovery from catastrophe, sharpening the first-hour assessment remains one of the most valuable interventions available, and this study adds a measured, cautiously optimistic data point to that effort.

Subject of Research: Prognostic value of admission severity scores, including the Burch–Wartofsky Point Scale, for predicting adverse in-hospital outcomes in thyroid storm

Article Title: Admission Burch–Wartofsky point scale and critical care scores as predictors of adverse in-hospital outcomes in thyroid storm: a retrospective observational study

Article References: Nagamine, T., Yada-Tanabe, T., Kobayashi, S., Nagao, M., Fukuda, I., Sugihara, H., & Iwabu, M. (2026). Admission Burch–Wartofsky point scale and critical care scores as predictors of adverse in-hospital outcomes in thyroid storm: a retrospective observational study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02614-2

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02614-2

Keywords: thyroid storm, Burch–Wartofsky Point Scale, APACHE II, SOFA, qSOFA, risk stratification, prognostic markers, critical care, hyperthyroidism, atrial fibrillation, organ failure, retrospective study

The study, published in BMC Cancer by a team led by Susanne von Kroge of University Medical Center Hamburg-Eppendorf together with collaborators at the Robert Koch Institute and the Hamburg Cancer Registry, drew on harmonized nationwide registry data covering the years 2020 through 2023, with vital status follow-up extending to December 2024. From a total of 16,443 patients diagnosed with a first primary diffuse large B-cell lymphoma, 10,872 began systemic therapy within 56 days of diagnosis and formed the primary analysis cohort. The median age was 71 years, 44.2 percent of patients were female, and the median follow-up lasted about a year and a half.

The researchers divided patients into groups according to the diagnosis-to-treatment interval, a measure epidemiologists call the DTI, ranging from treatment in the first week after diagnosis to initiation between weeks five and eight. Three-year overall survival across these five groups ranged from roughly 63 percent to 75 percent. On its face, that spread might seem to suggest that timing matters enormously. But when the team applied statistical models, the direction of the association was the opposite of what the urgency narrative would predict.

Using Kaplan-Meier survival curves and Cox proportional hazards regression, the investigators found that compared with patients treated in week one, those who started later had progressively lower hazards of death. Patients beginning therapy in week three had a 28 percent lower hazard of dying from any cause, with a hazard ratio of 0.72 and a 95 percent confidence interval of 0.64 to 0.81. Those starting in week four fared better still, at a hazard ratio of 0.63, and patients treated between weeks five and eight showed a hazard ratio of 0.62, or a 38 percent reduction. The confidence intervals in every case excluded one, indicating the associations were statistically robust.

To a clinician, such a pattern immediately raises a red flag of confounding. Doctors do not assign treatment dates at random. Patients with the most aggressive, bulky, or symptomatic disease are rushed into the infusion chair within days, while those with more indolent-appearing disease can safely wait for complete staging, cardiac assessments, and fertility discussions. If sicker patients are treated fastest, then early treatment will appear to worsen survival even if timing itself has no causal effect, a classic example of what epidemiologists call confounding by indication, or in this context, the waiting-time paradox.

The German team addressed this head-on by adjusting their models for patient, tumor, and structural characteristics, most importantly the International Prognostic Index, or IPI, the standard five-factor score that combines age, disease stage, number of extranodal sites, performance status, and lactate dehydrogenase levels. Low-risk IPI strongly predicted better survival, with a hazard ratio of 0.24 compared with high-risk disease. Even after this adjustment, a residual association between longer diagnosis-to-treatment intervals and improved survival persisted, hinting that the interval itself might carry independent prognostic information in patients with less aggressive disease.

Perhaps the most revealing part of the study is what predicted delay in the first place. The researchers modeled which factors pushed treatment later and found that low-risk IPI scores added an average of 7.89 days to the interval, while older age added 0.62 days per standard deviation. Patients who survived the first year had, on average, started treatment 3.26 days later than those who did not. In other words, the patients who waited longest were systematically the ones with the least threatening disease, and the ones treated most urgently were those whose lymphoma demanded immediate action.

Missing IPI data posed a methodological challenge that the authors handled with unusual care. Rather than discarding incomplete records, they treated missing IPI as a separate category and ran both complete-case and multiple-imputation sensitivity analyses to test whether their conclusions depended on how missingness was handled. The consistency of the results across these approaches strengthens the central finding that early initiation is primarily a marker of adverse disease biology rather than a driver of survival in its own right.

The implications for health policy and clinical practice are subtle but significant. In many healthcare systems, time-to-treatment is used as a quality indicator, with targets and audits pressing hospitals to start cancer therapy faster. For solid tumors with validated screening pathways, such metrics can be meaningful. But this study suggests that for diffuse large B-cell lymphoma, raw speed from diagnosis to treatment is a poor proxy for quality of care. Penalizing centers for longer intervals could perversely reward the triage of less sick patients while doing nothing for those with aggressive disease, who are already treated within days.

The authors conclude that early treatment in newly diagnosed DLBCL is primarily driven by adverse disease characteristics, and that the diagnosis-to-treatment interval may function as an independent prognostic factor mainly in less aggressive disease. The study was funded by the Innovationsfonds zur Förderung von Versorgungsforschung under grant number 01VSF25057, and the underlying data came from German state cancer registries used under legal provisions permitting scientific analysis of non-identifiable records. For the roughly 16,000 Germans diagnosed each year with this lymphoma, and for oncologists everywhere who feel the pressure of the clock, the message is a nuanced one: the calendar matters less than the biology, and a few extra days of careful preparation may be exactly what the least aggressive tumors allow, and what the most aggressive ones cannot afford.

Subject of Research: The association between the diagnosis-to-treatment interval and survival in newly diagnosed diffuse large B-cell lymphoma

Article Title: Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry study

Article References: von Kroge, S., Steinhaus, N. J., Bokemeyer, C., Tetzlaff, F., Walk, H., Kusche, H., LYSED study group, Klotz, S., Obi, N., Knesebeck, O. V., Beernink, M., Gundler, C., Ückert, F., Schulze, K., Augustin, J., Semmelhaack, R., Sassenberg-Gummert, A., & Peters, F. (2026). Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry study. BMC Cancer, 26(1), Article 1144. https://doi.org/10.1186/s12885-026-17024-9

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17024-9

Keywords: diffuse large B-cell lymphoma, diagnosis-to-treatment interval, treatment delay, immunochemotherapy, survival, International Prognostic Index, cancer registry, Cox regression, prognostic markers, waiting-time paradox, hematology, oncology

The concerns that triggered the retraction are strikingly specific and, to anyone familiar with laboratory practice, deeply troubling. According to the notice, the Migration image in the Control group partially overlaps with the Invasion image in the same group in Figure 3 of the paper. A second, parallel problem affects the experimental arm of the same figure: the Migration image in the siCCND3 group partially overlaps with the Invasion image in that group as well. In plain terms, two pairs of images that were supposed to document two distinct biological measurements in two distinct experimental conditions appear, at least in part, to be the same pictures. The editors concluded that these duplications undermined the reliability of the figure and, by extension, the paper’s central claims.

To understand why such duplication matters, it helps to understand what migration and invasion assays actually measure and why they are treated as independent lines of evidence. In cancer biology, a migration assay typically assesses the ability of cells to move across a surface or through a gap, often using a scratch wound or a porous membrane without any coating. An invasion assay asks a harder question: can the cells not only move but also digest their way through a matrix that mimics the extracellular barriers they would encounter in tissue, usually a layer of Matrigel or a similar basement-membrane substitute coating the membrane? The two assays are conceptually related but biologically distinct, and a paper arguing that silencing a gene alters cancer cell behavior is expected to show coherent, distinguishable changes in both. When the control-group migration image overlaps with the control-group invasion image, the two assays collapse into one measurement. When the same overlap appears in the knockdown group, the entire comparative framework of the experiment is called into question, because the reader can no longer tell whether the reported differences between conditions reflect biology or image handling.

The gene at the center of the retracted work, CCND3, encodes cyclin D3, one of three D-type cyclins that serve as regulatory subunits for cyclin-dependent kinases 4 and 6. These kinase complexes phosphorylate the retinoblastoma protein, releasing transcription factors that drive cells from the G1 phase of the cell cycle into DNA synthesis. Because D-type cyclins sit at the gateway to proliferation, their dysregulation has long been implicated in cancer, and the related cyclin D1 has become a well-established diagnostic and prognostic marker in several tumor types, most famously in mantle cell lymphoma and in certain breast cancers. Cyclin D3 has a more nuanced profile: it is essential for the development of certain immune cell lineages, it is amplified or overexpressed in subsets of lymphomas and other malignancies, and its role in breast cancer specifically has been debated in the literature. The retracted 2015 paper had positioned cyclin D3 as a predictor of disease-free survival in breast cancer patients, a claim that, if validated, could have influenced how clinicians stratify patients for follow-up intensity or adjuvant therapy decisions.

The retraction notice makes clear that the concerns were raised by the authors themselves following publication, a detail that distinguishes this case from many retractions initiated by external sleuths or journal readers. The notice states that concerns were raised by the authors, including but not limited to the two image-overlap issues in Figure 3, indicating that the listed problems may not be exhaustive. Equally notable is what the notice records about the authors’ subsequent behavior: the authors have not responded to any correspondence from the Editor about this retraction. That silence leaves the record without an author explanation for the duplicated images, without a corrected version, and without any authorial dissent from the retraction itself. Under the retraction guidelines that most major publishers follow, a retraction is not a finding of misconduct by the journal; it is a statement that the published record can no longer be trusted, and it stands regardless of whether authors cooperate.

The original study emerged from the Department of Breast Surgery at the Breast Cancer Institute of Fudan University Shanghai Cancer Center, one of China’s leading oncology institutions, with contributing authors also affiliated with the center’s Department of Pathology and with the Department of Oncology at Shanghai Medical College of Fudan University. The author list included Yayun Chi, Sheng Huang, Mengying Liu, Liang Guo, Xuxia Shen and Jiong Wu, with Chi, Huang and Liu credited as equal contributors and Wu listed as the corresponding author. The paper was published open access in 2015 as volume 15, article 89 of Cancer Cell International, under the DOI 10.1186/s12935-015-0245-6, and the retraction notice itself carries the DOI 10.1186/s12935-026-04480-3. Open-access articles are licensed under Creative Commons terms that permit wide sharing and reuse, which means retracted copies can circulate freely on repositories, course packs and preprint-style aggregators long after the retraction notice appears, a structural challenge that the scholarly publishing industry continues to grapple with through initiatives such as CrossMark, which flags the version-of-record status of a document to readers who encounter it elsewhere.

Retractions of this kind rarely arrive in isolation, and the eleven-year gap between publication and withdrawal invites questions about how such overlaps survived peer review in the first place. Peer reviewers evaluate the scientific logic, the novelty and the statistical presentation of a manuscript, but they are volunteers, typically unpaid, and they are rarely equipped with the software tools now used to detect image manipulation. Over the past decade, the field has developed increasingly sensitive approaches to figure forensics, including tools that scan manuscripts for duplicated regions within and across images, even when the duplicates have been rotated, flipped, resized or adjusted for brightness. Journals have also begun screening at submission rather than after publication. A partial overlap between a migration image and an invasion image is exactly the class of error such screening is designed to catch, and its detection a decade after publication illustrates both how far the technology has come and how much of the older literature remains unexamined.

For clinicians and researchers who cited the original paper, the retraction carries practical consequences. Systematic reviews and meta-analyses that aggregated prognostic markers for breast cancer may have incorporated the cyclin D3 disease-free survival findings, and those analyses now require revision to exclude the retracted data. Databases that track gene-disease associations and prognostic signatures will typically annotate the paper as withdrawn, but the speed and completeness of such updates vary. For patients, the direct clinical impact is likely limited, since a single retrospective biomarker study from 2015 would not, on its own, have established cyclin D3 as a standard clinical test; prognostic markers require independent validation in large, multi-institution cohorts before entering practice. The retraction nonetheless removes one data point from the evidence base and, more importantly, removes a claim that may have been cited as supporting evidence in downstream papers, a phenomenon known in the literature-watching community as citation contamination, where a retracted finding continues to accrue citations from authors unaware of its status.

The case also speaks to the specific vulnerabilities of functional assays in cancer research. Migration and invasion images, along with flow cytometry plots, western blots and colony-formation photographs, are among the most frequently implicated elements in retractions, because they are generated in large numbers, look superficially similar across conditions and are easy to mislabel or reuse when assembling multi-panel figures. The pattern in this retraction, where the duplication occurs within each experimental group rather than between groups, suggests the kind of assembly error that can arise when many images from the same experiment are sorted and placed into panels, though the notice does not speculate on cause, and no author explanation is on record. What the notice does establish is the editorial standard applied: when two supposedly distinct measurements within the same figure cannot be distinguished, the editors’ confidence in the results and conclusions is lost, and the appropriate remedy is withdrawal of the paper rather than correction, because the integrity of the underlying experiment cannot be reconstructed from the published images alone.

The retraction notice closes the chapter on a study that once contributed to the conversation about cyclin D3 and breast cancer prognosis, but it does not settle the underlying biology. Whether cyclin D3 expression genuinely stratifies disease-free survival in breast cancer remains an open empirical question that would need to be addressed by studies with verified, independently generated data. What the case does settle, for the record, is that the 2015 paper cannot serve as evidence in that conversation. Readers who encounter the original article, its PDF or its citations in the wild are directed to the retraction notice at Cancer Cell International, and the scholarly consensus it represents is unambiguous: the figure evidence no longer supports the conclusions, the authors have not contested the withdrawal, and the article now stands as a cautionary example of why image integrity, quiet as it may seem beside headlines about genes and survival, is the load-bearing wall of experimental science.

Subject of Research: Retraction of a 2015 breast cancer biomarker study on cyclin D3 and disease-free survival due to duplicated images

Article Title: Retraction Note: Cyclin D3 predicts disease-free survival in breast cancer

Article References: Chi, Y., Huang, S., Liu, M., Guo, L., Shen, X., & Wu, J. (2026). Retraction Note: Cyclin D3 predicts disease-free survival in breast cancer. Cancer Cell International, 26(1), Article 333. https://doi.org/10.1186/s12935-026-04480-3

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04480-3

Keywords: retraction, breast cancer, cyclin D3, CCND3, disease-free survival, image duplication, migration assay, invasion assay, Cancer Cell International, research integrity, prognostic markers, cell cycle

Tertiary lymphoid structures are organized aggregates of immune cells that form outside the conventional lymph nodes and spleen. In many solid tumors, they are viewed as encouraging signs: evidence that the immune system has mounted a localized, sustained response against the malignancy. These structures typically contain T cells and B cells arranged in patterns that resemble miniature lymphoid organs, sometimes even developing the germinal centers where antibodies are refined. In cancers such as melanoma, lung cancer, and breast cancer, the presence and density of TLS have repeatedly been linked to better responses to immunotherapy and improved survival. The brain, however, has long been considered an immunologically quiet environment, protected by the blood-brain barrier and populated by its own specialized immune cells, so the role of TLS in brain tumors has remained far less clear.

That gap is precisely what a team of neurosurgeons and researchers affiliated with Kunming Medical University and collaborating institutions in China set out to address. In a retrospective study published in the journal Cancer Immunology, Immunotherapy, the investigators analyzed tissue samples from 62 patients with isocitrate dehydrogenase, or IDH, wildtype glioblastoma who were treated at their institution between 2016 and 2023. IDH wildtype status defines the most aggressive and common form of glioblastoma in adults, and it is the subtype for which new prognostic tools are most urgently needed. The study was conducted in accordance with the Declaration of Helsinki, with ethics approval from the First Affiliated Hospital of Kunming Medical University and written informed consent obtained from all participants or their legal representatives.

The methodological heart of the study lies in how the researchers detected and classified these immune structures. Using standard hematoxylin and eosin staining alongside immunohistochemical staining for CD3, a marker of T cells, and CD20, a marker of B cells, the team identified TLS within resected tumor specimens. Rather than simply recording whether TLS were present or absent, the investigators went a step further and built a grading system that captured two dimensions: the quantity of the structures and their spatial distribution within the tumor region. This distinction matters because a TLS sitting in the peritumoral zone, the tissue surrounding the tumor, may reflect a different immunological situation than one embedded deep within the tumor mass itself, where it would be in direct contact with malignant cells.

The results were striking. TLS were present in 58.1 percent of the cohort, meaning that more than half of these patients carried organized immune structures in or around their tumors. When the researchers correlated TLS status with overall survival using Kaplan-Meier curves, they found that TLS presence, TLS grading, and the extent of surgical resection all showed statistically significant associations with survival outcomes, each reaching the threshold of P less than 0.05. The grading system proved particularly informative. Patients with higher TLS grades, and especially those whose structures were located within the tumor itself, corresponding to the highest category, Score 3, experienced significantly prolonged overall survival compared with patients lacking these structures or harboring only peritumoral ones.

To ensure that this association was not simply a statistical artifact driven by other clinical variables, the team turned to multivariate Cox regression analysis, a standard statistical technique that evaluates the independent contribution of each factor while controlling for the others. The analysis confirmed that TLS grading stood as an independent favorable prognostic factor for overall survival in this glioblastoma cohort. In practical terms, this means that even after accounting for variables such as the extent of resection, the grade of the TLS carried its own predictive weight. The extent of resection, which distinguishes total, subtotal, and partial removal of the tumor, also remained significantly correlated with survival, consistent with decades of neurosurgical evidence, but the TLS signal held its ground alongside it.

The implications of these findings extend beyond prognosis into the realm of treatment selection. Glioblastoma has been a notoriously poor responder to immune checkpoint inhibitors, the class of drugs that has revolutionized the treatment of many other cancers. One leading explanation is that the brain tumor microenvironment lacks the pre-existing immune infrastructure that such therapies require to work. TLS could represent exactly that infrastructure: a localized factory for generating and deploying tumor-specific immune cells. If patients whose tumors contain high-grade, intratumoral TLS are the ones with an already-primed immune response, they may be the subset most likely to benefit from intensified immunotherapeutic interventions, while patients without TLS might need strategies that first induce lymphoid neogenesis before checkpoint blockade could have any chance of success.

The authors are appropriately measured in their claims. They emphasize that the proposed TLS grading system provides a potential prognostic stratification tool for glioblastoma that warrants external validation, a crucial caveat in a field where promising single-institution findings sometimes fail to replicate in larger, independent cohorts. With 62 patients, the study is a meaningful proof of concept but not a definitive clinical standard. Standardizing how TLS are identified and scored across pathology laboratories, and testing the grading system in independent datasets from other centers, will be essential steps before it could inform treatment decisions at the bedside. The retrospective design also means that the findings demonstrate association rather than causation, and it remains possible that TLS are a marker of some other underlying biological difference rather than an active driver of better outcomes.

Even with those caveats, the study adds an important piece to the evolving picture of glioblastoma immunology. The tumor microenvironment, once viewed as a hostile wasteland for immune activity, is increasingly understood as a complex ecosystem where organized immune structures can and do form. The fact that the location of these structures, not just their number, carries prognostic weight suggests that the spatial architecture of the anti-tumor immune response matters, a principle that resonates with broader trends in cancer immunology where spatial biology is reshaping how tumors are classified. For a disease in which median survival has barely moved in decades, any new, independently validated prognostic factor is significant, and one that could also guide immunotherapy selection would be doubly valuable.

The research, published as an open-access article, was supported by funding from Kunming Medical University, the Health Commission of Yunnan Province, and related regional research programs. The authors reported no relevant financial or non-financial conflicts of interest. As the field moves forward, the challenge will be to translate this grading system from the research laboratory into routine pathology workflows, where hematoxylin and eosin slides and CD3 and CD20 stains are already standard tools. If external validation confirms what this cohort suggests, neuro-oncologists may one day look at a glioblastoma specimen not only for the features that define its malignancy, but for the quiet architecture of the immune response unfolding within it, and use that architecture to decide which patients need the most aggressive immunological reinforcements available.

Subject of Research: Tertiary lymphoid structures as prognostic biomarkers in IDH-wildtype glioblastoma

Article Title: Tertiary lymphoid structures (TLS) classification: a new perspective on glioblastoma patient’s prognosis

Article References: Meng, M., Li, Y., Dai, X., Yang, G., Li, Z., & Tang, Z. (2026). Tertiary lymphoid structures (TLS) classification: a new perspective on glioblastoma patient’s prognosis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04537-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04537-2

Keywords: glioblastoma, tertiary lymphoid structures, tumor microenvironment, prognostic markers, immunotherapy, IDH-wildtype, immunohistochemistry, overall survival, neuro-oncology, Cox regression, CD3, CD20

The letter responds directly to a recent study by Kirkham and colleagues, published in the same journal, that followed children with mild sleep-disordered breathing who were managed with watchful waiting rather than immediate surgery. That study identified prognostic factors associated with progression of the condition, and the Turkish authors contend that such findings are at risk of being misinterpreted. If a child carries a feature that predicts worsening over time, the intuitive leap is that removing the obstructing tonsillar and adenoid tissue early would prevent that worsening, and that high-risk children therefore stand to gain the most from adenotonsillectomy. Yılmaz and his colleagues argue that this leap is logically unsound, and they ground their objection in a well-established framework from clinical epidemiology: the distinction between prognostic and predictive markers.

The distinction was crystallized in a widely cited 2015 paper by Kristel Ballman in the Journal of Clinical Oncology, which the letter authors invoke. A prognostic marker tells you something about the likely course of a disease or condition regardless of which treatment the patient receives. A predictive marker, by contrast, tells you something about the differential effect of a specific treatment, identifying patients in whom the therapy works better or worse than it does in others. A tumor biomarker may signal aggressive disease in every patient who carries it, yet only randomized evidence can show whether that same biomarker identifies patients who respond to a particular drug. The two concepts answer different questions, and conflating them can lead to treatment decisions that are not supported by evidence.

Applied to pediatric sleep medicine, the logic becomes clear. If a child with mild sleep-disordered breathing has characteristics associated with a higher likelihood of progression, those characteristics are prognostic. They suggest the child’s symptoms may worsen whether or not surgery is performed. They do not demonstrate that surgery will produce a larger improvement in that child than in a low-risk child. Only a predictive analysis, ideally within a randomized trial that formally tests for an interaction between the risk factor and treatment assignment, can establish differential treatment benefit. Without such an interaction analysis, claiming that high-risk children derive greater benefit from adenotonsillectomy extrapolates beyond what the data can support.

This is not merely a statistical quibble, because the strongest available evidence on the question comes from a landmark randomized clinical trial. In 2023, Redline and colleagues published in JAMA the results of a randomized trial of adenotonsillectomy for snoring and mild sleep apnea in children, a study that grew out of the Pediatric Adenotonsillectomy Trial for Snoring, or PATS, protocol described by Wang and colleagues in BMJ Open in 2020. That trial randomized children with mild sleep-disordered breathing to surgery or to watchful waiting and evaluated outcomes including behavioral measures and symptom resolution. The letter authors point to this randomized evidence as the appropriate standard against which claims of differential benefit must be tested, rather than observational progression data from cohorts of children managed without surgery.

The stakes of the distinction are considerable. Adenotonsillectomy, while generally safe, is a real surgical intervention carried out under general anesthesia, with associated risks of bleeding, infection, pain and the considerable burden that surgery imposes on children and families. If clinicians begin triaging children toward surgery on the basis of prognostic risk alone, families may be counseled toward an operation on the mistaken understanding that their child is precisely the kind of patient who benefits most. Conversely, if genuine predictive markers of surgical benefit do exist, identifying them properly could spare low-benefit children an unnecessary operation while directing those who would truly gain toward timely treatment. Either way, the answer determines how thousands of pediatric consultations unfold each year.

The watchful waiting study that prompted the letter adds an important empirical dimension to the debate. By demonstrating that many children with mild sleep-disordered breathing who are managed without immediate surgery do not progress, and by characterizing which children are more likely to worsen, it provides clinicians with genuinely useful information about the natural history of the condition. Natural history data of this kind are exactly what prognostic research is designed to deliver. The letter authors do not dispute the value of that data; what they dispute is the inferential step of converting prognosis into treatment guidance. Knowing that a subset of children tends to worsen over time does not reveal whether early surgery would have altered that trajectory, because the children in the watchful waiting cohort were, by design, not operated on.

There is also a broader lesson here for how medical evidence travels. Findings from observational cohorts are frequently repurposed, in review articles, guidelines and clinical conversations, as justification for interventions they were never designed to evaluate. The prognostic-predictive framework offers a simple safeguard: before using a risk marker to justify treatment, ask whether the marker was shown to modify the effect of that treatment in a randomized comparison. In oncology, where the framework was formalized, this discipline has reshaped how biomarkers are validated and how targeted therapies are prescribed. Sleep medicine, the letter suggests, should adopt the same rigor, particularly for a condition as common and as variably managed as mild pediatric sleep-disordered breathing.

For now, the practical message for clinicians and families is one of calibrated caution. Mild sleep-disordered breathing in children sits on a spectrum that ranges from benign primary snoring to frank obstructive sleep apnea, and the decision to operate should rest on the best randomized evidence available, on the severity and impact of symptoms, and on shared decision making that weighs the known benefits and burdens of surgery. A child’s risk of progression is relevant information, but it is information about the disease, not about the treatment. As Yılmaz, Özer and Topal emphasize, until studies demonstrate that specific risk factors predict differential benefit from adenotonsillectomy, prognostic risk alone cannot establish that high-risk children have more to gain from the operation. The distinction may sound like semantics, but in the clinic it is the difference between evidence-based surgery and surgery based on an inferential shortcut.

Subject of Research: The distinction between prognostic and predictive risk markers in deciding adenotonsillectomy benefit for children with mild sleep-disordered breathing

Article Title: Prognostic risk does not establish greater adenotonsillectomy benefit in children with mild sleep-disordered breathing

Article References: Yılmaz, E., Özer, N. K., & Topal, E. (2026). Prognostic risk does not establish greater adenotonsillectomy benefit in children with mild sleep-disordered breathing. Journal of Clinical Sleep Medicine, 22(1), Article 176. https://doi.org/10.1007/s44470-026-00196-3

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00196-3

Keywords: adenotonsillectomy, pediatric sleep apnea, sleep-disordered breathing, prognostic markers, predictive markers, watchful waiting, randomized controlled trial, clinical decision making, snoring, biomarkers, evidence-based medicine, Journal of Clinical Sleep Medicine

Metastatic castration-resistant prostate cancer, abbreviated mCRPC, is the lethal stage of prostate disease in which tumors continue to grow despite androgen-deprivation treatment. The arrival of [177Lu]Lu-PSMA-617, a radiopharmaceutical that delivers beta radiation directly to prostate cancer cells expressing the prostate-specific membrane antigen, changed the treatment landscape after the pivotal VISION phase III trial established it as a standard of care. Yet the survival benefit varies enormously from one patient to the next. Some men live for years after treatment begins, while others progress within months. Weighing the potential benefit against the burden of repeated nuclear medicine cycles demands an honest estimate of prognosis, and that is precisely what a validated scoring system can provide.

The Bellmunt Risk Score was originally developed for a completely different cancer: metastatic urothelial carcinoma. In its original setting, it stratified patients with advanced transitional cell carcinoma who had failed platinum-based chemotherapy using three binary variables that are universally available in any oncology clinic. Each patient receives one point for an Eastern Cooperative Oncology Group performance status greater than zero, meaning any degree of functional impairment; one point for anemia, defined as a hemoglobin concentration below 10 grams per deciliter; and one point for the presence of liver metastases. The resulting score ranges from zero to three, with higher scores indicating worse expected survival. Its elegance lies in its simplicity: no specialized software, no genomic sequencing, no additional laboratory panels.

In a recent primary analysis, the same research group showed that the score translates surprisingly well to prostate cancer patients undergoing PSMA-targeted radioligand therapy. But a demonstration in the development cohort is only the first step. Clinical prediction models are notorious for performing well in the population where they were built and then faltering elsewhere, a phenomenon statisticians call overfitting. External validation in a genuinely independent patient population, treated under different institutional pathways and evaluated by investigators uninvolved in the original data collection, is the mandatory test of generalizability. The new study was designed to meet exactly that standard.

The validation cohort comprised 243 men with confirmed PSMA-positive metastatic castration-resistant prostate cancer who received at least one cycle of [177Lu]Lu-PSMA-617 at University Hospital Frankfurt, a tertiary high-volume center with no patient overlap with the original development cohort. The score was calculated at baseline, within twenty-eight days before the first therapy cycle. The patient population was heavily pretreated: 9.9 percent received radioligand therapy as the first treatment line for metastatic disease, 22.6 percent as the second, 39.1 percent as the third, and 28.4 percent in even later lines. Over a median follow-up of 17.7 months, 111 deaths occurred, corresponding to 45.7 percent of the cohort, providing substantial statistical power for survival analysis.

The results revealed a strikingly clean stepwise pattern. Patients with a score of zero, meaning none of the three risk factors, had an estimated median overall survival of 24.0 months. Each additional point shaved months off that figure: 15.8 months for a score of one, 11.2 months for a score of two, and 8.7 months for the small group of seven patients with all three risk factors. The Kaplan-Meier comparison across the four groups was highly significant, with a log-rank p value below 0.0001. In univariable analysis, compared with the low-risk group, the hazard ratio for death was 1.63 for score one, 3.38 for score two, and 5.30 for score three, and these estimates aligned closely with the hazard ratios observed in the original development cohort.

Because more heavily pretreated patients naturally have worse survival, the researchers adjusted their multivariable analysis for the number of prior treatment lines. Even after this adjustment, the score remained an independent predictor of survival. The hazard ratio was 3.04 for score two and 4.76 for score three, both statistically significant, while score one showed a non-significant trend at 1.49. Given that only seven patients fell into the highest-risk category, the team performed a sensitivity analysis using Firth’s penalized likelihood Cox regression, a method designed for small sample sizes, which confirmed the stability of the estimate with a hazard ratio of 5.10.

Predictive accuracy was assessed with two complementary metrics. Harrell’s concordance index for the multivariable model combining the score and treatment line reached 0.659, comparable to the performance achieved in the development cohort. Time-dependent receiver operating characteristic analysis, which evaluates discrimination at specific time points, yielded area-under-the-curve values of 69.3 percent for six-month survival, 71.3 percent for twelve-month survival, and 67.5 percent for twenty-four-month survival. Calibration for twelve-month survival, examined with two hundred bootstrap resamples, was excellent, with a mean absolute error of just 0.027 and a maximum absolute error of 0.059, meaning the predicted and observed survival probabilities were nearly identical.

The authors are candid about the study’s limitations. The retrospective design and the absence of a central review of imaging data introduce potential bias, since liver metastases were identified through local institutional interpretation of PSMA PET/CT scans. The multivariable model deliberately adjusted only for treatment lines, omitting established prognostic markers such as baseline PSA, lactate dehydrogenase, alkaline phosphatase, and quantitative metastatic burden, which leaves open the possibility of residual confounding. The researchers argue that this restraint was intentional: adding complex variables would risk overfitting and would compromise the score’s identity as a strictly clinical, standalone, bedside-ready tool. The very small size of the score-three subgroup also demands cautious interpretation of its survival estimates.

What emerges is a pragmatic message for oncology. More sophisticated nomograms that incorporate quantitative PSMA-PET volume metrics or extended biochemical panels may theoretically offer superior accuracy, but they require specialized software or additional laboratory costs and are often impractical in routine care. The Bellmunt Risk Score, by contrast, can be computed in seconds from information already gathered at every oncology visit. As indications for [177Lu]Lu-PSMA-617 expand into earlier treatment lines following trials such as ENZA-p, which tested the radioligand in combination with enzalutamide, the need for rapid risk stratification will only grow. The researchers emphasize that the score is intended to complement, not replace, comprehensive clinical and imaging assessment, serving primarily to guide patient expectations and support shared decision-making. With external validation now complete, a tool born in urothelial carcinoma has earned a place in the prostate cancer clinic, offering clinicians and patients alike a clear-eyed, evidence-based starting point for one of the most consequential conversations in modern cancer care.

Subject of Research: External validation of the Bellmunt Risk Score for predicting overall survival in metastatic castration-resistant prostate cancer patients undergoing lutetium-177 PSMA-617 radioligand therapy

Article Title: External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy

Article References: Büttner, T., Wenzel, M., Mandel, P., Schmitt, P., Hoffmann, C., Marinova, M., Essler, M., Chun, F. K. H., Ritter, M., Groener, D., & Krausewitz, P. (2026). External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08169-7

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08169-7

Keywords: metastatic castration-resistant prostate cancer, Bellmunt Risk Score, Lu-PSMA-617, radioligand therapy, survival prediction, prognostic markers, external validation, PSMA PET, overall survival, Kaplan-Meier analysis, Cox regression, nuclear medicine